Intracellular uptake of etoposide-loaded solid lipid nanoparticles induces an enhancing inhibitory effect on gastric cancer through mitochondria-mediated apoptosis pathway

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 3987-3998

  Wang, Jiao ^a   Zhu, Rongrong ^a   Sun, Xiaoyu ^a   Zhu, Yanjing ^a   Liu, Hui ^b   Wang, Shi Long ^a  

^a First Affiliated Hospital of Fourth Military Medical University   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Caspases; Cytochrome c; Gastric carcinoma; SLNs; Sustained profile

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 9; CYTOCHROME C; ETOPOSIDE; PROTEIN P53; SOLID LIPID NANOPARTICLE; DRUG CARRIER; LIPID; NANOPARTICLE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE; CELL MEMBRANE POTENTIAL; CONTROLLED STUDY; DISPERSION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ENTRAPMENT EFFICIENCY; DRUG LOADING; DRUG MECHANISM; DRUG STABILITY; EMULSION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; INTRACELLULAR TRANSPORT; MITOCHONDRIAL DYNAMICS; PARTICLE SIZE; PHARMACOLOGICAL PARAMETERS; PHYSICAL CHEMISTRY; SGC7901 CELL; STOMACH CANCER; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; INTRACELLULAR SPACE; METABOLISM; MITOCHONDRION; STOMACH TUMOR; TUMOR CELL LINE;

APOPTOSIS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ETOPOSIDE; HUMANS; INTRACELLULAR SPACE; LIPIDS; MITOCHONDRIA; NANOPARTICLES; PARTICLE SIZE; STOMACH NEOPLASMS;

EID: 84928740271     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S64103     Document Type: Article

References (51)

1. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease. BMC Cancer. 2002;2:37.
2. Johnson DH, Greco FA, Strupp J, Hande KR, Hainsworth JD. Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: a phase II trial. J Clin Oncol. 1990;8(10): 1613-1617.
3. Hande KR. Etoposide: four decades of development of topoisomerase II inhibitor. Eur J Cancer. 1998;34(10):1514-1521.
4. Sieber SM, Whang-Peng J, Botkin C, Knutsen T. Teratogenic and cytogenetic effects of some plant-derived antitumor agents (vincristine, colochicine, maytasine, VP-16-213 and VM-216) in mice. Teratology. 1978;18(1):31-47.
5. Gantchev TG, Hunting DJ. Enhancement of etoposide (VP-16) cytotoxicity by enzymatic and photodynamically induced oxidative stress. Anticancer Drugs. 1997;8(2):164-173.
6. Joel SP, Clark PI, Heap L, et al. Pharmacological attempts to improve the bioavailability of oral etoposide. Cancer Chemother Pharmacol. 1995;37(1-2):125-133.
7. Lorico A, Rappa G, Finch RA, Yang D, Flavell RA, Sartorelli AC. Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. Cancer Res. 1997;57(23):5238-5242.
8. Qin L, Wang M, Zhu R, You S, Zhou P, Wang S. The in vitro sustained release profile and antitumor effect of etoposide-layered docuble hydroxide nanohybrids. Int J Nanomedicine. 2013;8:2053-2064.
9. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760.
10. Wang X, Yang L, Chen ZG, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin. 2008;58(2):97-110.
11. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent. Cancer Res. 1986;46(12):6387-6392.
12. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2009;71(3):409-419.
13. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery ± a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-177.
14. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56(9):1257-1272.
15. Yang X, Liu Y, Liu C, Zhang N. Biodegradable solid lipid nanoparticle flocculates for pulmonary delivery of insulin. J Biomed Nanotechnol. 2012;8(5):834-842.
16. Marcato PD, Durán N. New aspects of nanopharmaceutical delivery systems. J Nanosci Nanotechnol. 2008;8(5):2216-2229.
17. Luo Y, Chen D, Ren L, Zhao X, Qin J. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control Release. 2006;114(1):53-59.
18. Yuan H, Miao J, Du YZ, You J, Hu FQ, Zeng S. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int J Pharm. 2008;348(1-2):137-145.
19. Wang S, Chen T, Chen R, Hu Y, Chen M, Wang Y. Emodin loaded solid lipid nanoparticles: Preparation, characterization and antitumor activity studies. Int J Pharm. 2012;430(1-2):238-246.
20. Bhushan S, Kakkar V, Pal HC, et al. Enhanced anticancer potential of encapsulated solid lipid nanoparticles of TPD: A novel triterpenediol from Boswellia serrata. Mol Pharm. 2013;10(1):225-235.
21. Zhu RR, Qin LL, Wang M, et al. Preparation, characterization, and anti-tumor property of podophyllotoxin-loaded solid lipid nanoparticles. Nanotechnology. 2009;20(5):055702.
22. Trotta M, Debernardi F, Caputo O. Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int J Pharm. 2003;257(1-2):153-160.
23. Souto EB, Almeida AJ, Müller RH. Lipid nanoparticles (SLN, NLC) for cutaneous drug delivery: structure, protection and skin effects. J Biomed Nanotechnol. 2007;3(4):317-331.
24. Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release. 2009;133(3):238-244.
25. Zhang H, Zhang FM, Yan SJ. Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles. Int J Nanomedicine. 2012;7:2901-2910.
26. Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas AG, Ithakissios DS. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release. 2002;79(1-3):123-135.
27. Wang W, Zhu R, Xie Q, et al. Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in Solid lipid nanoparticles. Int J Nanomedicine. 2012;7:3667-3677.
28. Zhong Z, Chen X, Tan W, et al. Germacrone inhibits the proliferation of breast cancer cell lines by inducing cell cycle arrest and promoting apoptosis. Eur J Pharmacol. 2011;667(1-3):50-55.
29. Munyendo WL, Zhang Z, Abbad S, et al. Micelles of TPGS modified apigenin phospholipid complex for oral administration: preparation, in vitro and in vivo evaluation. J Biomed Nanotechnol. 2013;9(12):2034-2047.
30. Vandita K, Shashi B, Santosh KG, Pal KI. Enhanced apoptotic effect of curcumin loaded solid lipid nanoparticles. Mol Pharm. 2012;9(12): 3411-3421.
31. Li YB, Lin ZQ, Zhang ZJ, et al. Protective, antioxidative and antiapoptotic effects of 2-methoxy-6-acetyl-7-methyljuglone from Polygonum cuspidatum in PC12 cells. Planta Med. 2011;77(4):354-361.
32. Qian WY, Sun DM, Zhu RR, Du XL, Liu H, Wang SL. pH-sensitive strontium carbonate nanoparticles as new anticancer vehicles for controlled etoposide release. Int J Nanomedicine. 2012;7:5781-5792.
33. Gao JL, He TC, Li YB, Wang YT. A traditional Chinese medicine formulation consisting of Rhizoma Corydalis and Rhizoma Curcumae exerts synergistic anti-tumor activity. Oncol Rep. 2009;22(5):1077-1083.
34. Ly JD, Grubb DR, Lawen A. The mitochondrial membrane potential (deltapsi(m)) in apoptosis; an update. Apoptosis. 2003;8(2):115-128.
35. Han L, Du LB, Kumar A, et al. Inhibitory effects of trolox-encapsulated chitosan nanoparticles on tertbutylhydroperoxide induced RAW264.7 apoptosis. Biomaterials. 2012;33(33):8517-8528.
36. Mohanty C, Sahoo SK. The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials. 2010;31(25):6597-6611.
37. Ramana LN, Sethuraman S, Ranga U, Krishnan UM. Development of a liposomal nanodelivery system for nevirapine. J Biomed Sci. 2010;17:57.
38. Fouad EA, El-badry M, Mahrous GM, Alsarra IA, Alashbban Z, Alanazi FK. In vitro investigation for embedding dextromethorphan in lipids using spray drying. Dig J Nanomater Biostruct. 2011;6(3): 1129-1139.
39. Cui S, Yin D, Chen Y, et al. In vivo targeted deep-tissue photodynamic therapy based on near-infrared light triggered upconversion nanoconstruct. ACS Nano. 2013;7(1):676-688.
40. Xue M, Yang MX, Zhang W, et al. Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles. Int J Nanomedicine. 2013;8:4677-4687.
41. Saxena V, Hussain MD. Polymeric mixed micelles for delivery of curcumin to multidrug resistant ovarian cancer. J Biomed Nanotechnol. 2013;9(7):1146-1154.
42. Natu MV, de Sousa HC, Gil MH. Effects of drug solubility, state and loading on controlled release in bicomponent electrospun fibers. Int J Pharm. 2010;397(1-2):50-58.
43. Zamani M, Morshed M, Varshosaz J, Jannesari M. Controlled release of metronidazole benzoate from poly e-caprolactone electrospun nanofibers for periodontal diseases. Eur J Pharm Biopharm. 2010;75(2):179-185.
44. Lee MK, Lim SJ, Kim CK. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials. 2007;28(12):2137-2146.
45. Chiu CC, Li CH, Ung MW, Fuh TS, Chen WL, Fang K. Etoposide (VP-16) elicits apoptosis following prolonged G2-M cell arrest in p53-mutated human non-small cell lung cancer cells. Cancer Lett. 2005;223(2):249-258.
46. Nam C, Doi K, Nakayama H. Etoposide induces G2/M arrest and apoptosis in neural progenitor cells via DNA damage and an ATM/p53-related pathway. Histol Histopathol. 2010;25(4):485-493.
47. Métivier D, Dallaporta B, Zamzami N, et al. Cytofluorometric detection of mitochondrial alterations in early CD95/Fas/APO-1-triggered apoptosis of Jurkat T lymphoma cells. Comparison of seven mitochondrion-specific fluorochromes. Immunol Lett. 1998;61(2-3):157-163.
48. Park JH, Kim TH. Release of cytochrome c from isolated mitochondria by etoposide. J Biochem Mol Biol. 2005;38(5):619-623.
49. Perkins CL, Fang G, Kim CN, Bhalla KN. The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res. 2000;60(6):1645-1653.
50. Karpinich NO, Tafani M, Rothman RJ, Russo MA, Farber JL. The Course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochromec. J Biol Chem. 2002;277(19):16547-16552.
51. Reed JC. Cytochrome c: can't live with it - can't live without it. Cell. 1997;91(5):559-562.